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Abstract— A series of 11 unsymmetrical dinucleoside dicarboxylate conjugates of nucleoside reverse transcriptase inhibitors were
synthesized. Three dicarboxylic acids, succinic acid, suberic acid and 1,14-tetradecandioc acid, were diesterified with either 3′-azido2′,3′-dideoxythymidine (AZT), 3′-fluoro-2′,3′-dideoxythymidine (FLT), 2',3'-dideoxy-3'-thiacytidine (3TC) or 5-fluoro-2',3'-dideoxy-3'thiacytidine (FTC). The anti-HIV activity of synthesized compounds was evaluated against HIV-1 X4 (IIIB) and R5 (BaL) viral strains in
single-round infection assays. Results indicated that the tetradecandioate esters of nucleosides were more active against HIV than the
corresponding parent nucleosides and nucleoside conjugates. The tetradecandioate conjugate of FLT and FTC (5) was found to be the
most potent compound with EC50 values of 47 and 75 nM against X4 and R5 HIV-1 strains, respectively, while the EC50 values for the
parent analogs, FLT and FTC, ranged from 700 to 3,300 nM.

Acquired immunodeficiency syndrome (AIDS) is an
immune disorder caused by the attack of human
immunodeficiency virus (HIV) on immune cells, such as
T-lymphocytes dendritic cells, and macrophages.1,2 HIV
uses its two envelope proteins gp120 and gp41 to bind to
these immune cells via the CD4 receptor and the
chemokine coreceptors CCR5 and CXCR4.1-4
Depending on the type of coreceptors used for viral
binding to the cell membrane, HIV can be classified into
two categories: R5 and X4 strains, which bind to CCR5
and CXCR4 coreceptors, respectively.4 R5 strains
predominate among those establishing primary infection
at cervicovaginal and colorectal mucosa.5 After entry
into the cell, the virus uses a reverse transcriptase (RT)
to copy its RNA and produce viral DNA copies which
integrate in the cellular genome, transcribe and produce
new virions.1,2
Even though the efforts to find proper treatment
against HIV started more than three decades ago, the
search for effective drugs still continues.2 Since the
beginning, the RT enzyme has been a target for
development of effective therapy and several
antiretroviral drugs have been introduced and approved
as inhibitors of RT Nucleoside reverse transcriptase
inhibitors (NRTIs) such as zidovudine (3'-azido-3'deoxythymidine, AZT), lamivudine (2',3'-dideoxy-3'thiacytidine, 3TC) and stavudine (2',3'-didehydro-2',3'dideoxythymidine, d4T) were the first and the only
1
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category of antiretroviral drugs (ARVs) approved by
FDA until 1995 for HIV treatment (Figure 1).6 In
following years, several other categories of drugs such
as non-nucleoside reverse transcriptase inhibitors,
integrase strand transfer inhibitors, and protease
inhibitors were introduced in the market.2,6 Currently,
NRTIs such as emtricitabine (2',3'-dideoxy-5-fluoro-3'thiacytidine, FTC)
and tenofovir are used in
combination with these other categories of ARVs as part
of highly active antiretrovrial therapy (HAART) to
improve synergy and reduce resistance.. FTC (Figure 1)
is a highly potent NRTI and the last approved by FDA in
this category. Alovudine (3'-azido-3' deoxythymidine,
FLT, Figure 1) is also another highly potent NRT
inhibitor. Even though FLT has never been approved for
its clinical use against HIV, it remains a drug of interest
due to its potency and resistance profile.7-9
Lipophilic derivatives of nucleoside analogues have
been used to modulate the pharmacological behavior of
NRTIs for better biodistribution and improved
accumulation at target sites.10,11 Prodrug modifications
of NRTI drugs could be used to improve
pharmacokinetics and to enhance their delivery to
difficult-to-reach HIV reservoirs.12,13 In our earlier
studies, we have reported the synthesis of long-chain
acyl esters of 3TC,14 d4T,10 and FTC.15 These studies
indicated a significant increase in the antiviral activities
of fatty acyl esters against their parent nucleosides. In

later studies, we incorporated 2-3 nucleosides in one
molecule using various spacers such as amino acids and
peptides.16 Synthesis of lipophilic derivatives containing
two different anti-HIV nucleosides would allow for the
generation of asymmetrical conjugates that can provide
simultaneous delivery of two nucleoside analogs,
improve their resistance profile, and generate synergistic
activity. The selection of the nucleosides was based on
their potency and resistance profile.

Scheme 1. Synthesis of unsymmetrical 5•,5•
,5•-dinucleoside 1,14tetradecanoate esters of FLT with FTC (4) and 3TC (5): (a) 1,14tetradecandioic acid, HBTU, DIPEA, DMF, rt, 4 h; (b) 3TCDMTr/FTC-DMTr, HBTU, DIPEA, DMF, rt, 6 h; (c) TFA in
acetic acid (2%, v/v), rt, 1 h.

FLT and N4-protected FTC (FTC-DMTr) were first
coupled with an excess of 1,14-tetradecandioic acid to
obtain the mono-substituted product (1 and 6,
respectively). FLT-tetradecanoate (1) was further
coupled with either FTC-DMTr or 3TC-DMTr followed
by removal of protecting group to produce conjugates
FLT-C14-FTC (4) and FLT-C14-3TC (5; Scheme 1).
DMTr-FTC-tetradecanoate (6) was coupled with 3TCDMTr, and the protective group was removed to
produce FTC-C14-3TC (8, Scheme 2).
Figure 1. Chemical structures of zidovudine (AZT), lamivudine
(3TC), stavudine (d4T), alovudine (FLT), and emtricitabine
(FTC).

In a recent study, we screened symmetrical
dinucleoside dicarboxylate conjugates against HIV.17
We found that in most cases, the presence of two
nucleosides on a fatty acyl chain did not affect the
overall anti-HIV activity. However, the diesters of
tetradecanoic acid were more active than the parent
nucleoside and the corresponding shorter chain
nucleoside conjugates. Based on these results, in the
current study, we have synthesized unsymmetrical
dinucleoside conjugates of 1,14-tetradecandioic acid
(C14) with three highly active antiviral agents FLT, FTC,
and 3TC. We also synthesized similar symmetrical and
unsymmetrical short (C4) and intermediate chain (C8)
conjugates for comparative studies against X4 and R5
HIV-1 strains. Lipophilic conjugates were expected to
display better membrane interaction, show improved
cellular uptake, release two different nucleosides
intracellularly, and provide an overall synergistic effect.
Schemes 1-5 depict the synthesis of dinucleosidefatty acid conjugates. Unsymmetrical dinucleoside 1,14tetradecandioate derivatives of FLT, 3TC and FTC were
synthesized by reaction of nucleosides with 1,14tetradecandioic acid in the presence of HBTU as a
coupling agent (Schemes 1 and 2). Both 3TC-DMTr and
FTC-DMTr were synthesized using the previously
published procedure.14,15

Scheme 2. Synthesis of unsymmetrical 5•,5•
,5•-dinucleoside 1,14tetradecandioate esters of FTC with 3TC (8): (a) 1,14tetradecandioic acid, HBTU, DIPEA, DMF, rt, 4 h; (b) 3TCDMTr, HBTU, DIPEA, DMF, rt, 6 h; (c) TFA in acetic acid (2%,
v/v), rt, 1 h.

Similarly, succinate esters of AZT, FLT and 3TC
were synthesized by coupling FLT-succinate with AZT
(FLT-C4-AZT, 9) and 3TC-DMTr and by coupling AZTsuccinate with 3TC-DMTr. Protective group (DMTr)
was removed in situ to produce FLT-C4-3TC (10) and
AZT-C4-3TC (11) (Scheme 3).
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Scheme 3. Synthesis of unsymmetrical 5•,5•
,5•-dinucleoside 1,4succinate derivatives of FLT, AZT, and 3TC. (a) AZT, HBTU,
DIPEA, DMF, rt, overnight; (b) 3TC-DMTr, HBTU, DIPEA,
DMF, rt, overnight; (c) acetic acid (80% in water, v/v), 80 oC, 1 h.

Corresponding symmetrical dinucleoside 1,4succinate derivatives of FLT (FLT-C4-FLT, 12) and
AZT (AZT-C4-AZT, 13) were synthesized by reaction of
nucleosides with succinyl chloride (Scheme 4).
Symmetrical dinucleoside 1,8-suberates (14-16, Scheme
5) were synthesized by reacting two equivalents of
nucleosides, FLT, AZT, or DMTr-3TC, with one
equivalent of suberic acid and removing protecting
group in 3TC conjugate (16).

Scheme 4. Synthesis of symmetrical 5•,5•
,5•-dinucleoside 1,4succinate derivatives of FLT (12) and AZT (13). (a) FLT/AZT,
succinyl chloride, DMAP, benzene, rt, overnight.

Scheme 5. Synthesis of symmetrical 5•,5•
,5•-dinucleoside 1,8suberate derivatives of FLT (14), AZT (15), and 3TC (16). (a)
HBTU, suberic acid, DIPEA, DMF, rt, overnight; (b) acetic acid
(80% in water, v/v), 80 oC, 1 h.

All the intermediates and final conjugates were
purified by silica gel normal phase chromatography
using DCM/methanol eluent. Final conjugates were
further purified for higher purity by reverse phase high
performance
liquid
chromatography
using
water/methanol as gradient solvent eluents. The purity of
the final products was confirmed by analytical HPLC
(95-99% pure) with detection at 265 nm wavelength.
Targeted synthesized compounds were tested for
their cytotoxicity and anti-HIV activity against cell-free
virus (X4 and R5 strains) (Table 1). In general, the
synthesized compounds showed no significant cytotoxic
effects against target cells as shown in MTS cytotoxic
assays.
As shown in Table 1, the unsymmetrical conjugates
of the FLT, 3TC and FTC with tetradecandioic acid (4, 5
and 8) showed high antiviral activity (0.047-0.18 µM),
being significantly more potent than their parent
nucleoside analogues (0.7-32.7 µM). Although all three
conjugates were highly active against R5 strains of HIV
(EC50 ~ 0.07 µM), only conjugate 5 was very active
against X4 strains with an EC50 value of 0.047 µM. FLTC14-FTC (5) was the most potent molecule among the
studied conjugates with an EC50 of 47 nM and 75 nM
against IIIB and BaL strains of HIV, respectively. It was
clear that the conjugates of nucleosides with higher
activity against HIV such as FLT and FTC resulted in
high antiviral activity. Also, simply introducing a fatty
acid group on a nucleoside drug did not improve its
activity. Conjugate 5 was 38 and 7 times more potent
when compared to mono FLT-tetradecanoate derivative
(1) with EC50 values of 1.8 µM against HIV IIIB and
0.55 µM against HIV BaL, respectively.

Table 1. Anti-HIV Activity of dicarboxylic acid nucleoside conjugates.

Compd.
AZT
FLT

Cytotoxicitya

HIV-1 IIIbb

HIV-1 BaLc

CC50 (µ
µ M)

EC50 (µ
µ M)

EC50 (µ
µ M)

3'-azido-2',3'-dideoxythymidine

>374

34.4

129

3'-fluoro-2',3'-deoxythymidine

>410

0.8

3.3

Description

3TC

2',3'-dideoxy-3'-thiacytidine

80.3

32.7

11.3

FTC

5-fluoro-2',3'-dideoxy-3'-thiacytidine

>200

1.9

0.7

1

FLT-C13-COOH

>61

1.8

0.55

4

FLT-C14-3TC

>43

0.1

0.070

5

FLT-C14-FTC

>42

0.047

0.075

8

3TC-C14-FTC

>43

0.18

0.073

9

AZT-C4 -FLT

>168

14.7

17.5

10

3TC-C4-FLT

>180

44.5

42.2

11

3TC-C4-AZT

>173

16.1

19.2

12

FLT-C4-FLT

>175

3.7

3.0

13

AZT-C4 -AZT

>162

14.0

68.1

14

FLT-C8-FLT

>160

0.4

0.5

15

AZT-C8 -AZT

>148

0.2

<0.15

16

3TC-C8-3TC

>168

26.6

4.7

a

Cytotoxicity assay (MTT), CC50 (50% toxic concentration); bSingle-round infection assay (lymphocytotropic strain; X4-strain), EC50 (50% effective
concentration; cSingle-round infection assay (monocytotropic strain; R5-strain). In the single-round infection assay, compounds, virus and cells were
incubated for 2 hours. Cells were then washed and cultured for additional 48 h. Infection was measured by HIV-LTR driven galactosidase expression.
DMSO and dextran sulfate were used as negative and positive controls, respectively. All the assays were carried out in triplicate (n = 3).

Anti-HIV activities of tetradecandioic acid esters were
compared with the short chain (C4), symmetrical and
unsymmetrical succinate esters of FLT, AZT and 3TC.
The unsymmetrical dioate nucleoside conjugates
containing the succinate linker (9-13) (EC50 = 3-68 µM)
M)
were not as potent as those with the longer spacers.
These results indicate that the prodrug formation
through succinate linker approach is not efficient
enough to improve the antiviral activity of nucleosides.
Results were in agreement with our previous studies
where long chain fatty acid esters showed higher
activity than those with short chain esters. Conjugates 4,
5 and 8 were also compared with moderate chain length
(C8) conjugates of dinucleosides FLT, AZT and 3TC
(14-16). Even though suberate esters of dinucleoside
(14-16, EC50 <0.15-26 µM)
M) showed higher activity
against HIV than the parent nucleosides (EC50 = 0.8-129
µM)
M) and the corresponding succinate derivatives (9-13,
(
EC50 = 3-68 µM),
M), their activity was still weaker than that
of tetradecanoate diesters (4, 5, 8; EC50 = 0.047-0.18
µM). Suberate derivatives of AZT (15, EC50 <0.15-0.2
µM)
M) showed a significant improvement in antiviral
activity in comparison with both AZT (EC50 = 34-129
µM)
M) and the corresponding succinate derivative (13,
(
EC50 = 14-68 µM).
M).
In conclusion, conjugation of two different NRTIs
through 1,14-tetradecandioic acid spacer resulted in
conjugates with antiviral activities in the 0.047-0.18 µM
M
range. Conjugates with C14 chain showed significantly
improved antiviral activity in comparison to their parent
nucleosides and suberic acid (C8 chain) and succinic
acid (C4 chain). Conjugate FLT-C14-FTC (5, EC50 =

0.047-0.075 µM)
M) was the most active conjugate in this
series. In our earlier studies on FLT, d4T, FTC, and
3TC esters of long chain fatty acids, we explained the
effect of the lipophilic nature of the synthesized esters
in improving cellular uptake and antiviral activity. In
this study, tetradecandioic acid esters have longer
carbon chain length spacer and are more lipophilic than
suberic acid and succinate esters. Based on these
findings, within the boundaries of the analogs tested, it
can be concluded that longer chain length spacers
between nucleosides analogues improved antiviral
activity. Tetradecandioic acid was found to be an
optimal linker for the improved potency of synthesized
dinucleoside prodrugs, possibly due to the improved
cellular uptake.
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Graphical Abstract
The synthesis of unsymmetrical long chain dicarboxylate esters of dinucleoside reverse transcriptase
inhibitors and their anti-HIV activities are reported.
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